TMEM97 (Transmembrane Protein 97), also known as the sigma-2 receptor (σ2R), is a protein encoded by the TMEM97 gene. Initially identified as a binding site for neurosteroids and psychotropic drugs, it gained attention for its role in cholesterol homeostasis, cellular stress responses, and cancer biology. TMEM97 antibodies are critical tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are typically developed against specific epitopes, such as the N-terminal or C-terminal regions, and validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry.
Research using TMEM97 antibodies has revealed its overexpression in certain cancers, including breast, ovarian, and prostate malignancies, where it correlates with tumor progression and poor prognosis. Its involvement in cholesterol trafficking and interaction with the LDL receptor pathway has also linked it to neurodegenerative diseases like Alzheimer’s. Recent structural studies using cryo-EM have resolved TMEM97’s binding pockets for small molecules, further driving interest in its therapeutic targeting. Antibodies against TMEM97 help validate these findings, enabling the exploration of its role as a biomarker or therapeutic target. However, specificity validation remains crucial due to homology with other transmembrane proteins and potential cross-reactivity. Ongoing studies aim to refine antibody performance and expand applications in drug discovery and mechanistic research.